2024

• Garrett, T., Gilchrist, J., McKenzie, A., Ali, F., Danon, J., Werry, E., Kassiou, M. (2024). An Investigation on Linker Modifications of Cyanoguanidine-Based P2X7 Receptor Antagonists. ChemMedChem: chemistry enabling drug discovery, 19(17), e202400163. [More Information]
• Villemagne, V., Rowe, C., Doré, V., Chong, L., Kassiou, M., Mulligan, R., Feizpour, A., Taylor, J., Roesner, M., Miller, T. (2024). Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals. Journal of Alzheimer's Disease, 97(3), 1463-1475. [More Information]
• Alzghool, O., Aarnio, R., Helin, J., Wahlroos, S., Keller, T., Matilainen, M., Solis, J., Danon, J., Kassiou, M., Snellman, A., et al (2024). Correction to: Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA (EJNMMI Research, (2024), 14, 1, (25), 10.1186/s13550-024-01085-7). EJNMMI Research, 14(1). [More Information]
• Carey-Smith, S., Simad, M., Panchal, K., Aya-Bonilla, C., Smolders, H., Lin, S., Armitage, J., Nguyen, V., Bentley, K., Ford, J., Montgomery, A., Kassiou, M., et al (2024). Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. Haematologica, 109(7), 2309-2315. [More Information]
• Dhar, K., Townsend, B., Montgomery, A., Danon, J., Pagan, J., Kassiou, M. (2024). Enhancing CNS mitophagy: drug development and disease-relevant models. Trends In Pharmacological Sciences. [More Information]
• Chan, B., Lynch, N., Tran, W., Joyce, J., Savage, G., Meutermans, W., Montgomery, A., Kassiou, M. (2024). Fragment-based drug discovery for disorders of the central nervous system: designing better drugs piece by piece. Frontiers in Chemistry, 12. [More Information]
• Alzghool, O., Aarnio, R., Helin, J., Wahlroos, S., Keller, T., Matilainen, M., Solis, J., Danon, J., Kassiou, M., Snellman, A., et al (2024). Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA. EJNMMI Research, 14(1). [More Information]
• Lee, E., Besnier, M., Genetzakis, E., Tang, O., Kott, K., Vernon, S., Gray, M., Grieve, S., Kassiou, M., Figtree, G. (2024). High-Throughput Measure of Mitochondrial Superoxide Levels as a Marker of Coronary Artery Disease to Accelerate Drug Translation in Patient-Derived Endothelial Cells Using Opera Phenix® Technology. International Journal of Molecular Sciences, 25(1). [More Information]
• Sullivan, M., Lane, S., McKenzie, A., Ball, S., Sunde, M., Neely, G., Moreno, C., Maximova, A., Werry, E., Kassiou, M. (2024). iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype. Journal of Neuroinflammation, 21(1). [More Information]
• Sparkes, E., Maloney, C., Markham, J., Dane, C., Boyd, R., Gilchrist, J., Moir, M., Gordon, R., Luo, J., Pike, E., Walker, K., Kassiou, M., McGregor, I., Kevin, R., Hibbs, D., Jorgensen, W., Banister, S., Cairns, E., Ametovski, A. (2024). Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA. ACS Chemical Neuroscience, 15(11), 2160-2181. [More Information]
• Giladi, M., Montgomery, A., Kassiou, M., Danon, J. (2024). Structure-based drug design for TSPO: Challenges and opportunities. Biochimie, 224, 41-50. [More Information]
• John Hamilton, A., Treiger Sredni, S., Saxena, A., Gunosewoyo, H., Lane, S., Werry, E., Suri, A., Bailey, A., Mercé, C., Kadolsky, U., Kassiou, M., et al (2024). Synthesis and Antitumour Evaluation of Tricyclic Indole-2-Carboxamides against Paediatric Brain Cancer Cells. ChemMedChem: chemistry enabling drug discovery. [More Information]
• Dane, C., Cumbers, G., Allen, B., Montgomery, A., Danon, J., Kassiou, M. (2024). Unlocking therapeutic potential: The role of adamantane in drug discovery. Australian Journal of Chemistry, 77(8), CH24075. [More Information]

2023

• Montgomery, A., Joyce, J., Danon, J., Kassiou, M. (2023). An update on late-stage functionalization in today’s drug discovery. Expert Opinion on Drug Discovery, 18(6), 597-613. [More Information]
• Rubin, L., Du, Y., Sweeney, S., O'Toole, R., Thomas, C., Zandi, A., Shinehouse, L., Brosnan, M., Nam, H., Burke, M., Kassiou, M., et al (2023). Imaging Brain Injury in Former National Football League Players. JAMA Network Open, 6(10), e2340580. [More Information]
• Castellino, N., Montgomery, A., Danon, J., Kassiou, M. (2023). Late-stage Functionalization for Improving Drug-like Molecular Properties. Chemical Reviews, 123(13), 8127-8153. [More Information]
• Beltran-Lobo, P., Kassiou, M., Golde, T., Hanger, D., Verkhratsky, A., Perez-Nievas, B., Noble, W., Hughes, M., Troakes, C., Croft, C., et al (2023). P2X7R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes. Brain, Behavior, and Immunity, 114, 414-429. [More Information]
• Ball, S., Adamson, J., Sullivan, M., Zimmermann, M., Lo, V., Sanz-Hernandez, M., Jiang, X., Kwan, A., McKenzie, A., Werry, E., Kassiou, M., Rutledge, P., Sunde, M., et al (2023). Perphenazine-Macrocycle Conjugates Rapidly Sequester the Aβ42 Monomer and Prevent Formation of Toxic Oligomers and Amyloid. ACS Chemical Neuroscience, 14(1), 87-98. [More Information]
• Brumberg, J., Aarnio, R., Forsberg, A., Marjamäki, P., Kerstens, V., Moein, M., Nag, S., Wahlroos, S., Kassiou, M., Windhorst, A., et al (2023). Quantification of the purinergic P2X7 receptor with [11C]SMW139 improves through correction for brain-penetrating radiometabolites. Journal of Cerebral Blood Flow and Metabolism, 43(2), 258-268. [More Information]
• Kallinen, A., Mardon, K., Lane, S., Montgomery, A., Bhalla, R., Stimson, D., Ahamed, M., Cowin, G., Hibbs, D., Werry, E., Fulton, R., Kassiou, M., et al (2023). Synthesis and Preclinical Evaluation of Fluorinated 5-Azaindoles as CB2 PET Radioligands. ACS Chemical Neuroscience, 14(16), 2902-2921. [More Information]
• Reekie, T., Kassiou, M. (2023). Synthetic cannabinoid receptor agonists: An overview. In Vinood B. Patel, Victor R. Preedy, Colin R. Martin (Eds.), Neurobiology and Physiology of the Endocannabinoid System, (pp. 493-504). London: Elsevier. [More Information]
• Sullivan, M., Lane, S., Volkerling, A., Engel, M., Werry, E., Kassiou, M. (2023). Three-dimensional bioprinting of stem cell-derived central nervous system cells enables astrocyte growth, vasculogenesis, and enhances neural differentiation/function. Biotechnology and Bioengineering, 120(10), 3079-3091. [More Information]

2022

• Katzeff, J., Bright, F., Phan, K., Kril, J., Ittner, L., Kassiou, M., Hodges, J., Piguet, O., Kiernan, M., Halliday, G., Kim, W. (2022). Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 145(5), 1598-1609. [More Information]
• Genetzakis, E., Gilchrist, J., Kassiou, M., Figtree, G. (2022). Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease? Pharmacology & Therapeutics, 237, 108228. [More Information]
• Asih, P., Poljak, A., Kassiou, M., Ke, Y., Ittner, L. (2022). Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. PloS One, 17(5), e0254296. [More Information]
• Werry, E., Kassiou, M. (2022). Measuring Affinity of Ligands to the Oxytocin Receptor Using Radioligand Binding. Methods in Molecular Biology, (pp. 231-245). [More Information]
• Aarnio, R., Alzghool, O., Wahlroos, S., O'Brien-Brown, J., Kassiou, M., Solin, O., Rinne, J., Forsback, S., Haaparanta-Solin, M. (2022). Novel plasma protein binding analysis method for a PET tracer and its radiometabolites: A case study with [11C]SMW139 to explain the high uptake of radiometabolites in mouse brain. Journal of Pharmaceutical and Biomedical Analysis, 219, 114860. [More Information]
• Jackson, A., Werry, E., O'Brien-Brown, J., Schiavini, P., Wilkinson, S., Wong, E., McKenzie, A., Maximova, A., Kassiou, M. (2022). Pharmacological characterization of a structural hybrid P2X7R antagonist using ATP and LL-37. European Journal of Pharmacology, 914, 174667. [More Information]
• McKenzie, A., Garrett, T., Werry, E., Kassiou, M. (2022). Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 13(10), 1479-1490. [More Information]
• Callis, T., Garrett, T., Montgomery, A., Danon, J., Kassiou, M. (2022). Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 65(20), 13483-13504. [More Information]
• Ma, B., Montgomery, A., Chen, B., Kassiou, M., Danon, J. (2022). Strategies for targeting the P2Y12 receptor in the central nervous system. Bioorganic & Medicinal Chemistry Letters, 71, 128837. [More Information]
• Kallinen, A., Kassiou, M. (2022). Tracer development for PET imaging of proteinopathies. Nuclear Medicine and Biology, 114-115, 115-127. [More Information]
• Werry, E., Bright, F., Kassiou, M. (2022). TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. In Philip V. Peplow, Bridget Martinez, Thomas A. Gennarelli (Eds.), Neurodegenerative Diseases Biomarkers, (pp. 407-427). New York: Humana, New York, NY. [More Information]
• Cheng, H., Callis, T., Montgomery, A., Danon, J., Jorgensen, W., Ke, Y., Ittner, L., Werry, E., Kassiou, M. (2022). Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies. International Journal of Molecular Sciences, 23(23). [More Information]

2021

• Patkar, O., Mohamed, A., Narayanan, A., Mardon, K., Cowin, G., Bhalla, R., Stimson, D., Kassiou, M., Beecher, K., Belmer, A., et al (2021). A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. Scientific Reports, 11(1), 1-11. [More Information]
• Danon, J., Tregeagle, D., Kassiou, M. (2021). Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa. Australian Journal of Chemistry, 74(11), 749-757. [More Information]
• Munoz, L., Gurgis, F., Akerfeldt, M., Kassiou, M. (2021). Novel agents for cancer therapy with dual mechanism of action. Patent No. 15/547227, 15/547227, 2020205331. .
• Duggan, P., Kassiou, M. (2021). Cannabis and Cannabinoids. Australian Journal of Chemistry, 74(6), 367-368. [More Information]
• Chen, B., McCuaig-Walton, D., Tan, S., Montgomery, A., Day, B., Kassiou, M., Munoz, L., Recasens, A. (2021). Dyrk1a negatively regulates CDK5-SOX2 pathway and self-renewal of glioblastoma stem cells. International Journal of Molecular Sciences, 22(8), 4011-1-4011-14. [More Information]
• Recasens, A., Humphrey, S., Ellis, M., Hoque, M., Abbassi, R., Chen, B., Longworth, M., Needham, E., James, D., Johns, T., Kassiou, M., Yang, P., Munoz, L., et al (2021). Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. Cell Death Discovery, 7(1), 81. [More Information]
• Bladen, C., Mirlohi, S., Santiago, M., Longworth, M., Kassiou, M., Banister, S., Connor, M. (2021). Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. Neuropharmacology, 187, 108478. [More Information]
• Chaney, A., Lopez-Picon, F., Serrière, S., Wang, R., Bochicchio, D., Webb, S., Vandesquille, M., Harte, M., Georgiadou, C., Lawrence, C., Reekie, T., Kassiou, M., et al (2021). Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: A collaborative multi-modal study. Theranostics, 11(14), 6644-6667. [More Information]
• Maximova, A., Werry, E., Kassiou, M. (2021). Senolytics: A novel strategy for neuroprotection in als? International Journal of Molecular Sciences, 22(21), 12078. [More Information]
• Alsayed, S., Suri, A., Bailey, A., Lane, S., Werry, E., Huang, C., Yu, L., Kassiou, M., Sredni, S., Gunosewoyo, H. (2021). Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. RSC Medicinal Chemistry, 12(11), 1910-1925. [More Information]
• Kassiou, M., Reekie, T., Scott, M. (2021). Methods for Synthesis of Phytocannabinoids. Patent No. 10807931, 371123. , India.
• Moir, M., Lane, S., Montgomery, A., Hibbs, D., Connor, M., Kassiou, M. (2021). The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist. European Journal of Medicinal Chemistry, 210, 113087. [More Information]
• Ariawan, D., Au, C., Paric, E., Fath, T., Ke, Y., Kassiou, M., van Eersel, J., Ittner, L. (2021). The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors. Frontiers in Chemistry, 9, 781213. [More Information]
• Sheikh, Z., Bradbury, P., Reekie, T., Pozzoli, M., Robinson, P., Kassiou, M., Young, P., Ong, H., Traini, D. (2021). Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 902, 174098. [More Information]

2020

• Katzeff, J., Bright, F., Lo, K., Kril, J., Connolly, A., Crossett, B., Ittner, L., Kassiou, M., Loy, C., Hodges, J., Piguet, O., Kiernan, M., Halliday, G., Kim, W. (2020). Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 10(1), 13741. [More Information]
• Upton, D., Popovic, K., Fulton, R., Kassiou, M. (2020). Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. Scientific Reports, 10(1), 9366. [More Information]
• Sachdev, S., Banister, S., Santiago, M., Bladen, C., Kassiou, M., Connor, M. (2020). Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research & Perspectives, 8(2), e00566. [More Information]
• Lepelletier, F., Vandesquille, M., Asselin, M., Prenant, C., Robinson, A., Mann, D., Green, M., Barnett, E., Banister, S., Mottinelli, M., Kassiou, M., et al (2020). Evaluation of 18F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue. Theranostics, 10(18), 7938-7955. [More Information]
• Lacapere, J., Duma, L., Finet, S., Kassiou, M., Papadopoulos, V. (2020). Insight into the Structural Features of TSPO: Implications for Drug Development. Trends In Pharmacological Sciences, 41(2), 110-122. [More Information]
• Gillis, A., Gondin, A., Kliewer, A., Sanchez, J., Lim, H., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmidel, F., Katte, T., Reekie, T., Kassiou, M., Christie, M., et al (2020). Low Intrinsic Efficacy for G Protein Activation Can Explain the Improved Side Effect Profiles of New Opioid Agonists. Science Signaling, 13(625), 1-18. [More Information]
• Ryan, P., Xu, M., Jahan, K., Davey, A., Bharatam, P., Anoopkumar-Dukie, S., Kassiou, M., Mellick, G., Rudrawar, S. (2020). Novel Furan-2-yl-1H-pyrazoles Possess Inhibitory Activity against á - Synuclein Aggregation. ACS Chemical Neuroscience, 11(15), 2303-2315. [More Information]
• Ryan, P., Xu, M., Davey, A., Kassiou, M., Mellick, G., Rudrawar, S. (2020). O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on á-synuclein aggregation. Bioorganic Chemistry, 94, 1-8. [More Information]
• Przybyla, M., Van Eersel, J., van Hummel, A., van der Hoven, J., Sabale, M., Harasta, A., Müller, J., Gajwani, M., Prikas, E., Mueller, T., Kassiou, M., et al (2020). Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Brain, 143(6), 1889-1904. [More Information]
• Beaino, W., Janssen, B., Kooijman, E., Vos, R., Schuit, R., O'Brien-Brown, J., Kassiou, M., van het Hof, B., Vugts, D., de Vries, H., et al (2020). PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 17(1), 300. [More Information]
• Galletta, M., Reekie, T., Nagalingam, G., Bottomley, A., Harry, E., Kassiou, M., Triccas, J. (2020). Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 9(8), 1-11. [More Information]
• Vo, S., Banister, S., Freelander, I., Werry, E., Reekie, T., Ittner, L., Kassiou, M. (2020). Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 11(4), 511-517. [More Information]
• Green, D., Eyre, H., Singh, A., Taylor, J., Chu, J., Jeys, L., Sumathi, V., Coonar, A., Rassl, D., Babur, M., Reekie, T., Kassiou, M., et al (2020). Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene, 39(33), 5553-5569. [More Information]
• Hansen, T., Galougahi, K., Besnier, M., Genetzakis, E., Tsang, M., Finemore, M., O'Brien-Brown, J., Di Bartolo, B., Kassiou, M., Bubb, K., Figtree, G. (2020). The Novel P2X7 Receptor PKT100 Improves Right Ventricular Function and Survival in Pulmonary Hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 319(1), H183-H191. [More Information]
• Hagens, M., Golla, S., Janssen, B., Vugts, D., Beaino, W., Windhorst, A., O'Brien-Brown, J., Kassiou, M., Shuit, R., Schwarte, L., et al (2020). The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man stud. European Journal of Nuclear Medicine and Molecular Imaging, 47(2), 379-389. [More Information]
• McGregor, I., Kassiou, M., Bowen, M., Hicks, C., Jorgensen, W. (2020). Novel small molecules that target social impairment and addictions (SOC 1). Patent No. 2715384. Russian Federation.
• Sokias, R., Werry, E., Cheng, A., Lloyd, J., Sohler, G., Danon, J., Montgomery, A., Du, J., Gao, Q., Hibbs, D., Reekie, T., Kassiou, M., et al (2020). Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 207, 112725. [More Information]

2019

• Moir, M., Danon, J., Reekie, T., Kassiou, M. (2019). An overview of late-stage functionalization in today's drug discovery. Expert Opinion on Drug Discovery, 14(11), 1137-1149. [More Information]
• Danon, J., Reekie, T., Kassiou, M. (2019). Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 1(6), 612-624. [More Information]
• Ke, Y., Chan, G., Stefanoska, K., Au, C., Bi, M., Muller, J., Przybyla, M., Feiten, A., Prikas, E., Halliday, G., Piguet, O., Kiernan, M., Kassiou, M., Hodges, J., Loy, C., Kril, J., Sutherland, G., et al (2019). CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 294(38), 14149-14162. [More Information]
• Reekie, T., Williams, C., Rendina, L., Kassiou, M. (2019). Cubanes in medicinal chemistry. Journal of Medicinal Chemistry, 62(3), 1078-1095. [More Information]
• Cheng, H., Sokias, R., Werry, E., Ittner, L., Reekie, T., Du, J., Gao, Q., Hibbs, D., Kassiou, M. (2019). First nondiscriminating translocator protein ligands produced from a carbazole scaffold. Journal of Medicinal Chemistry, 62(17), 8235-8248. [More Information]
• Vinh, N., Drinkwater, N., Malcolm, T., Kassiou, M., Lucantoni, L., Grin, P., Butler, G., Duffy, S., Overall, C., Avery, V., et al (2019). Hydroxamic acid inhibitors provide cross-species inhibition of Plasmodium M1 and M17 aminopeptidases. Journal of Medicinal Chemistry, 62(2), 622-640. [More Information]
• Bruijnen, S., Verweij, N., Gent, Y., Huisman, M., Windhorst, A., Kassiou, M., van de Ven, P., Lammertsma, A., Hoekstra, O., Voskuyl, A., et al (2019). Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PloS One, 14(9), 1-12. [More Information]
• Sachdev, S., Vemuri, K., Banister, S., Longworth, M., Kassiou, M., Santiago, M., Makriyannis, A., Connor, M. (2019). In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors. British Journal of Pharmacology, 176(24), 4653-4665. [More Information]
• Bright, F., Werry, E., Dobson-Stone, C., Piguet, O., Ittner, L., Halliday, G., Hodges, J., Kiernan, M., Loy, C., Kassiou, M., Kril, J. (2019). Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 15(9), 540-555. [More Information]
• Longworth, M., Reekie, T., Blakey, K., Boyd, R., Connor, M., Kassiou, M. (2019). New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicology, 37(2), 350-365. [More Information]
• Ryan, P., Xu, M., Davey, A., Danon, J., Mellick, G., Kassiou, M., Rudrawar, S. (2019). O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chemical Neuroscience, 10(5), 2209-2221. [More Information]
• Qiao, L., Fisher, E., McMurray, L., Sephton, S., Hird, M., Kuzhuppilly-Ramakrishnan, N., Williamson, D., Zhou, X., Werry, E., Kassiou, M., et al (2019). Radiosynthesis of (R,S)-[18F]GE387: A potential PET radiotracer for imaging translocator protein 18 kDa (TSPO) with low binding sensitivity to the human gene polymorphism rs6971. ChemMedChem: chemistry enabling drug discovery, 14(9), 982-993. [More Information]
• Werry, E., Bright, F., Piguet, O., Ittner, L., Halliday, G., Hodges, J., Kiernan, M., Loy, C., Kril, J., Kassiou, M. (2019). Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. International Journal of Molecular Sciences, 20(13), 3161. [More Information]
• Moir, M., Lane, S., Lai, F., Connor, M., Hibbs, D., Kassiou, M. (2019). Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry, 180, 291-309. [More Information]
• Franz, F., Jechle, H., Wilde, M., Angerer, V., Huppertz, L., Longworth, M., Kassiou, M., Jung, M., Auwarter, V. (2019). Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. Forensic Toxicology, 37(2), 316-329. [More Information]
• Moir, M., Boyd, R., Gunosewoyo, H., Montgomery, A., Connor, M., Kassiou, M. (2019). Synthesis and evaluation of various heteroaromatic benzamides as analogues of -ylidene-benzamide cannabinoid type 2 receptor agonists. Tetrahedron Letters, 60(36), 1-7. [More Information]
• Kallinen, A., Boyd, R., Lane, S., Bhalla, R., Mardon, K., Stimson, D., Werry, E., Fulton, R., Connor, M., Kassiou, M. (2019). Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. Organic and Biomolecular Chemistry, 17(20), 5086-5098. [More Information]
• Pyrczak-Felczykowska, A., Narlawar, R., Pawlik, A., Guzow-Krzeminska, B., Artymiuk, D., Hac, A., Rys, K., Rendina, L., Reekie, T., Herman-Antosiewicz, A., Kassiou, M. (2019). Synthesis of usnic acid derivatives and evaluation of their antiproliferative activity against cancer cells. Journal of Natural Products, 82(7), 1768-1778. [More Information]
• Gulliver, D., Werry, E., Reekie, T., Katte, T., Jorgensen, W., Kassiou, M. (2019). Targeting the oxytocin system: New pharmacotherapeutic approaches. Trends In Pharmacological Sciences, 40(1), 22-37. [More Information]

2018

• Hoque, M., Abbassi, R., Froio, D., Man, J., Johns, T., Stringer, B., Day, B., Pajic, M., Kassiou, M., Munoz, L. (2018). Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacological Research, 134, 166-178. [More Information]
• Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2018). Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin-and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 143, 1644-1656. [More Information]
• Mogler, L., Franz, F., Rentsch, D., Angerer, V., Weinfurtner, G., Longworth, M., Banister, S., Kassiou, M., Moosmann, B., Auwarter, V. (2018). Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Drug Testing and Analysis, 10(1), 196-205. [More Information]
• Zhou, Q., Reekie, T., Abbassi, R., Indurthi Venkata, D., Font Sadurni, J., Ryan, R., Rendina, L., Munoz, L., Kassiou, M. (2018). Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells. Australian Journal of Chemistry, 71(10), 789-797. [More Information]
• Janssen, B., Vugts, D., Wilkinson, S., Ory, D., Chalon, S., Hoozemans, J., Schuit, R., Beaino, W., Kooijman, E., van den Hoek, J., Kassiou, M., et al (2018). Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 8(1), 1-10. [More Information]
• Coughlin, J., Yang, T., Rebman, A., Bechtold, K., Du, Y., Mathews, W., Lesniak, W., Mihm, E., Frey, S., Marshall, E., Reekie, T., Kassiou, M., et al (2018). Imaging glial activation in patients with post-treatment Lyme disease symptoms: A pilot study using [11C]DPA-713 PET. Journal of Neuroinflammation, 15(1), 1-7. [More Information]
• Hagens, M., Golla, S., Wijburg, M., Yaqub, M., Heijtel, D., Steenwijk, M., Schober, P., Breve, J., Schuit, R., Reekie, T., Kassiou, M., et al (2018). In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. Journal of Neuroinflammation, 15(1), 1-10. [More Information]
• Beckers, L., Ory, D., Geric, I., Declercq, L., Koole, M., Kassiou, M., Bormans, G., Baes, M. (2018). Increased expression of translocator protein (TSPO) marks pro-inflammatory microglia but does not predict neurodegeneration. Molecular Imaging and Biology, 20(1), 94-102. [More Information]
• Chaney, A., Bauer, M., Bochicchio, D., Smigova, A., Kassiou, M., Davies, K., Williams, S., Boutin, H. (2018). Longitudinal investigation of neuroinflammation and metabolite profiles in the APPswexPS1De9 transgenic mouse model of Alzheimer’s disease. Journal of Neurochemistry, 144(3), 318-335. [More Information]
• Henderson, F., Hart, P., Pradillo, J., Kassiou, M., Christie, L., Williams, K., Boutin, H., McMahon, A. (2018). Multi-modal imaging of long-term recovery post-stroke by positron emission tomography and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Communications in Mass Spectrometry, 32(9), 721-729. [More Information]
• Ryan, P., Patel, B., Makwana, V., Jadhav, H., Kiefel, M., Davey, A., Reekie, T., Rudrawar, S., Kassiou, M. (2018). Peptides, peptidomimetics, and carbohydrate-peptide conjugates as amyloidogenic aggregation inhibitors for Alzheimer's disease. ACS Chemical Neuroscience, 9(7), 1530-1551. [More Information]
• Narlawar, R., Austin, C., Kahlert, J., Selleri, S., Da Pozzo, E., Martini, C., Werry, E., Rendina, L., Kassiou, M. (2018). Remarkable enhancement in boron uptake within glioblastoma cells with carboranyl-indole carboxamides. Chemistry: An Asian Journal, 13(21), 3321-3327. [More Information]
• Jorgensen, W., Munoz, L., Kassiou, M. (2018). CNS permeable anti cancer tubulin inhibitors. Patent No. AU2018900313, AU2018900315, AU2018900315. .
• Zhou, Q., Reekie, T., Abbassi, R., Indurthi Venkata, D., Font Sadurni, J., Ryan, R., Munoz, L., Kassiou, M. (2018). Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A. Bioorganic and Medicinal Chemistry, 26(22), 5852-5869. [More Information]
• Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]
• Reekie, T., Scott, M., Kassiou, M. (2018). The evolving science of phytocannabinoids. Nature Reviews. Chemistry, 2(1), 1-12. [More Information]
• Callis, T., Reekie, T., O'Brien-Brown, J., Wong, E., Werry, E., Elias, N., Jorgensen, W., Tsanaktsidis, J., Rendina, L., Kassiou, M. (2018). The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 74(12), 1207-1219. [More Information]
• Notter, T., Coughlin, J., Gschwind, T., Weber-Stadbauer, U., Wang, Y., Kassiou, M., Vernon, A., Benke, D., Pomper, M., Sawa, A., et al (2018). Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry, 23(2), 323-334. [More Information]

2017

• Katte, T., Kassiou, M. (2017). A patent review of oxytocin receptor antagonists 2013-2017. Expert Opinion on Therapeutic Patents, 27(12), 1287-1290. [More Information]
• Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
• Sridharan, S., Lepelletier, F., Trigg, W., Banister, S., Reekie, T., Kassiou, M., Gerhard, A., Hinz, R., Boutin, H. (2017). Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. Molecular Imaging and Biology, 19(1), 77-89. [More Information]
• Werry, E., King, V., Barron, M., Banister, S., Sokias, R., Kassiou, M. (2017). Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. European Journal of Pharmaceutical Sciences, 96, 186-192. [More Information]
• Sokias, R., Werry, E., Chua, S., Reekie, T., Munoz, L., Wong, E., Ittner, L., Kassiou, M. (2017). Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm (Medicinal Chemistry Communications), 8(1), 202-210. [More Information]
• O'Brien-Brown, J., Jackson, A., Reekie, T., Barron, M., Werry, E., Schiavini, P., McDonnell, M., Munoz, L., Wilkinson, S., Noll, B., Kassiou, M., et al (2017). Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 130, 433-439. [More Information]
• Ioppolo, J., Giboureau, N., Bhadbhade, M., Morrison, D., Kassiou, M., Rendina, L. (2017). Efficient radiosynthesis of a [18F]-phosphonium salt containing closo-carborane. Tetrahedron Letters, 58(46), 4367-4371. [More Information]
• Coughlin, J., Wang, Y., Minn, I., Bienko, N., Ambinder, E., Xu, X., Peters, M., Dougherty, J., Vranesic, M., Kassiou, M., et al (2017). Imaging of glial cell activation and white matter integrity in brains of active and recently retired national football league players. JAMA Neurology, 74(1), 67-74. [More Information]
• Katte, T., Reekie, T., Werry, E., Jorgensen, W., Boyd, R., Wong, E., Gulliver, D., Connor, M., Kassiou, M. (2017). Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 136, 330-333. [More Information]
• Gunosewoyo, H., Yu, L., Munoz, L., Kassiou, M. (2017). Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 9(3), 303-314. [More Information]
• Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Kassiou, M. (2017). Peptide molecules for the treatment of mental illness. Patent No. AU2017903935.
• Ahmed, R., Irish, M., van Eersel, J., Ittner, A., Ke, Y., Volkerling, A., van der Hoven, J., Tanaka, K., Karl, T., Kassiou, M., Kril, J., Piguet, O., Kiernan, M., Halliday, G., Hodges, J., et al (2017). Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 74, 126-138. [More Information]
• Wang, Y., Coughlin, J., Ma, S., Endres, C., Kassiou, M., Sawa, A., Dannals, R., Petri, M., Pomper, M. (2017). Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography. Lupus, 26(2), 170-178. [More Information]
• Jorgensen, W., Bowen, M., McGregor, I., Werry, E., Reekie, T., Kassiou, M. (2017). Small molecule treatments for mental illness. Patent No. International PCT WO2017004674 A1, International PCT WO2017004674 A1, International PCT/AU2017/051371. .
• Wong, E., Reekie, T., Werry, E., O'Brien-Brown, J., Bowyer, S., Kassiou, M. (2017). Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 27(11), 2439-2442. [More Information]
• Wilkinson, S., Barron, M., O'Brien-Brown, J., Janssen, B., Stokes, L., Werry, E., Chishty, M., Skarratt, K., Ong, J., Hibbs, D., Fuller, S., Kassiou, M., et al (2017). Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 receptor antagonist. ACS Chemical Neuroscience, 8(11), 2374-2380. [More Information]
• Longworth, M., Banister, S., Boyd, R., Kevin, R., Connor, M., McGregor, I., Kassiou, M. (2017). Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chemical Neuroscience, 8(10), 2159-2167. [More Information]
• Reekie, T., Wilkinson, S., Law, V., Hibbs, D., Ong, J., Kassiou, M. (2017). Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. Organic and Biomolecular Chemistry, 15(3), 576-580. [More Information]
• Moir, M., Chua, S., Reekie, T., Martin, A., Ittner, A., Ittner, L., Kassiou, M. (2017). Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm (Medicinal Chemistry Communications), 8(6), 1275-1282. [More Information]
• Zhou, Q., Phoa, A., Abbassi, R., Hoque, M., Reekie, T., Font Sadurni, J., Ryan, R., Stringer, B., Day, B., Johns, T., Munoz, L., Kassiou, M. (2017). Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) inglioblastoma. Journal of Medicinal Chemistry, 60(5), 2052-2070. [More Information]
• Longworth, M., Connor, M., Banister, S., Kassiou, M. (2017). Synthesis and pharmacological profiling of the metabolites of synthetic cannabinoid drugs APICA, STS-135, ABD-PINACA, and 5F-ADB-PINACA. ACS Chemical Neuroscience, 8(8), 1673-1680. [More Information]
• Chua, S., Cornejo, A., van Eersel, J., Stevens, C., Vaca, I., Cueto, M., Kassiou, M., Gladbach, A., Macmillan, A., Lewis, L., et al (2017). The polyphenol altenusin inhibits in vitro fibrillization of tau and reduces induced tau pathology in primary neurons. ACS Chemical Neuroscience, 8(4), 743-751. [More Information]

2016

• Conroy, T., Manohar, M., Gong, Y., Wilkinson, S., Webster, M., Lieberman, B., Banister, S., Reekie, T., Mach, R., Rendina, L., Kassiou, M. (2016). A systematic exploration of the effects of flexibility and basicity on sigma (sigma) receptor binding in a series of substituted diamines. Organic and Biomolecular Chemistry, 14(39), 9388-9405. [More Information]
• Thomas, C., Vercouillie, J., Domene, A., Tauber, C., Kassiou, M., Guilloteau, D., Destrieux, C., Serriere, S., Chalon, S. (2016). Detection of neuroinflammation in a rat model of subarachnoid hemorrhage using [18F]DPA-714 PET imaging. Molecular Imaging, 15, 1-8. [More Information]
• Przybyla, M., Stevens, C., Hoven, J., Harasta, A., Bi, M., Ittner, A., Hummel, A., Hodges, J., Piguet, O., Karl, T., Kassiou, M., et al (2016). Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 631, 24-29. [More Information]
• Jorgensen, W., Gulliver, D., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2016). Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. European Journal of Medicinal Chemistry, 108, 730-740. [More Information]
• Coughlin, J., Wang, Y., Ambinder, E., Ward, R., Minn, I., Vranesic, M., Kim, P., Ford, C., Higgs, C., Hayes, L., Kassiou, M., et al (2016). In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 6(4), 1-8. [More Information]
• Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., McGregor, I. (2016). MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology, Biochemistry and Behavior, 150-151, 115-123. [More Information]
• Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]
• Dupont, A., Guilloteau, D., Kassiou, M., Ribeiro, M., Vercouillie, J., Katsifis, A., Arlicot, N. (2016). Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 40(1), 72-81. [More Information]
• Kandemir, H., Sengul, I., Gardner, C., Werry, E., Barron, M., Kassiou, M., Kumar, N., Black, D. (2016). Synthesis of 7,7'-linked-bis-indoles via 7-tryptamines. Heterocycles, 93(1), 333-346. [More Information]
• Longworth, M., Banister, S., Mack, J., Glass, M., Connor, M., Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 34(2), 286-303. [More Information]
• Katte, T., Reekie, T., Jorgensen, W., Kassiou, M. (2016). The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. The Journal of Organic Chemistry, 81(11), 4883-4889. [More Information]
• Beinat, C., Banister, S., Herrera, M., Kassiou, M. (2016). The recent development of α7 nicotinic acetylcholine receptor (nAChR) ligands as therapeutic candidates for the treatment of central nervous system (CNS) diseases. Current Pharmaceutical Design, 22(14), 2134-2151. [More Information]

2015

• Serriere, S., Tauber, C., Vercouillie, J., Mothes, C., Pruckner, C., Guilloteau, D., Kassiou, M., Domene, A., Garreau, L., Page, G., et al (2015). Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 36(4), 1639-1652. [More Information]
• Wilkinson, S., Banister, S., Kassiou, M. (2015). Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Australian Journal of Chemistry, 68(1), 4-8. [More Information]
• Austin, C., Moir, M., Kahlert, J., Smith, J., Jamie, J., Kassiou, M., Rendina, L. (2015). Carborane-containing hydroxyamidine scaffolds as novel inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). Australian Journal of Chemistry, 68(12), 1866-1870. [More Information]
• Abbassi, R., Johns, T., Kassiou, M., Munoz, L. (2015). DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. Pharmacology & Therapeutics, 151, 87-98. [More Information]
• Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. [More Information]
• Banister, S., Beinat, C., Wilkinson, S., Shen, B., Bartoli, C., Selleri, S., Da Pozzo, E., Martini, C., Chin, F., Kassiou, M. (2015). Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). European Journal of Medicinal Chemistry, 93, 392-400. [More Information]
• Santiago-Ribeiro, M., Vercouillie, J., Cottier, J., Debiais, S., Bonnaud, I., Annan, M., Maia, S., Kassiou, M., Arlicot, N., Guilloteau, D. (2015). Evaluation en TEP de l'activation microgliale apres un accident vasculaire cerebral. Medecine Nucleaire, 39(3), 210-210. [More Information]
• Narlawar, R., Werry, E., Scarf, A., Hanani, R., Chua, S., King, V., Barron, M., Martins, R., Ittner, L., Rendina, L., Kassiou, M. (2015). First demonstration of positive allosteric-like modulation at the human wild type translocator protein (TSPO). Journal of Medicinal Chemistry, 58(21), 8743-8749. [More Information]
• Lee, D., Yue, X., Ibrahim, W., Lentz, M., Peterson, K., Jagoda, E., Kassiou, M., Maric, D., Reid, W., Hammoud, D. (2015). Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. Journal of Neuroinflammation, 12(171), 1-11. [More Information]
• Coughlin, J., Wang, Y., Munro, C., Ma, S., Yue, C., Chen, S., Airan, R., Kim, P., Adams, A., Garcia, C., Kassiou, M., et al (2015). Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 74, 58-65. [More Information]
• Munoz, L., Kavanagh, M., Phoa, A., Heng, B., Dzamko, N., Chen, E., Doddareddy, M., Guillemin, G., Kassiou, M. (2015). Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 95, 29-34. [More Information]
• Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]
• Phoa, A., Brown, S., Gurgis, F., Akerfeldt, M., Debber, A., Renn, C., Peifer, C., Stringer, B., Day, B., Wong, C., Chircop (nee Fabbro), M., Kassiou, M., Munoz, L., et al (2015). Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochemical Pharmacology, 98(4), 587-601. [More Information]
• Manohar, M., Banister, S., Beinat, C., O'Brien-Brown, J., Kassiou, M. (2015). Recent advances in the development of sigma-1 receptor ligands. Australian Journal of Chemistry, 68, 600-609. [More Information]
• Beinat, C., Reekie, T., Banister, S., O'Brien-Brown, J., Xie, T., Olson, T., Xiao, Y., Harvey, A., O'Connor, S., Coles, C., Kassiou, M., et al (2015). Structure-activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at alpha7 nAChRs through incorporation of known structural motifs. European Journal of Medicinal Chemistry, 95, 277-301. [More Information]
• Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. [More Information]
• Beinat, C., Banister, S., Herrera, M., Law, V., Kassiou, M. (2015). The therapeutic potential of alpha7 nicotinic acetylcholine receptor (apha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs, 29(7), 529-542. [More Information]
• Werry, E., Barron, M., Kassiou, M. (2015). TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 43, 531-536. [More Information]
• Hicks, C., Ramos, L., Reekie, T., Narlawar, R., Kassiou, M., McGregor, I. (2015). WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 232, 2659-2667. [More Information]

2014

• Medran-Navarrete, V., Bernards, N., Kuhnast, B., Damont, A., Pottier, G., Peyronneau, M., Kassiou, M., Marguet, F., Puech, F., Boisgard, R., et al (2014). [18F]DPA-C5yne, a novel fluorine-18-labelled analogue of DPA-714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 57(6), 410-418. [More Information]
• Liang, V., Ullrich, M., Lam, H., Chew, Y., Banister, S., Song, X., Zaw, T., Kassiou, M., Goetz, J., Nicholas, H. (2014). Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome. Cellular and Molecular Life Sciences, 71(17), 3339-3361. [More Information]
• Ullrich, M., Liang, V., Chew, Y., Banister, S., Song, X., Zaw, T., Lam, H., Berber, S., Kassiou, M., Nicholas, H., Goetz, J. (2014). Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans. Nature Protocols, 9(9), 2237-2255. [More Information]
• Hicks, C., Ramos, L., Reekie, T., Misagh, G., Narlawar, R., Kassiou, M., McGregor, I. (2014). Body temperature and cardiac changes induced by peripherally administered oxytocin, vaspressin and the non-peptide oxytocin receptor agonist WAY 267, 464: a biotelemetry study in rats. British Journal of Pharmacology, 171(11), 2868-2887. [More Information]
• Ribeiro, M., Vercouillie, J., Debiais, S., Cottier, J., Bonnaud, I., Camus, V., Banister, S., Kassiou, M., Arlicot, N., Guilloteau, D. (2014). Could 18F DPA 714 PET imaging be interesting to use in the early post-stroke period? European Journal of Nuclear Medicine and Molecular Imaging, 4(28), 1-8. [More Information]
• Zavitsanou, K., Lim, C., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S., Guillemin, G., Weickert, C. (2014). Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX2 inhibition. Brain, Behavior, and Immunity, 41, 173-181. [More Information]
• Beinat, C., Reekie, T., Hibbs, D., Xie, T., Olson, T., Xiao, Y., Harvey, A., O'Connor, S., Coles, C., Tsanaktsidis, J., Kassiou, M. (2014). Investigations of amide bond variation and biaryl modification in analogues of alpha7 nAChR agonist SEN12333. European Journal of Medicinal Chemistry, 84, 200-205. [More Information]
• Barron, M., Werry, E., McGregor, I., Kassiou, M. (2014). P2X7 in Bipolar and Depressive Disorders. In Norbert Weiss, Alexandra Koschak (Eds.), Pathologies of Calcium Channels, (pp. 635-661). Berlin: Springer-Verlag. [More Information]
• Gent, Y., Weijers, K., Molthoff, C., Windhorst, A., Huisman, M., Kassiou, M., Jansen, G., Lammertsma, A., van der Laken, C. (2014). Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 16(2), 1-9. [More Information]
• Reekie, T., McGregor, I., Kassiou, M. (2014). Pyrazolo 1,4 diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 55(33), 4568-4571. [More Information]
• Coughlin, J., Wang, Y., Ma, S., Yue, C., Kim, P., Adams, A., Roosa, H., Gage, K., Stathis, M., Rais, R., Kassiou, M., et al (2014). Regional brain distribution of translocator protein using 11C DPA-713 PET in individuals infected with HIV. Journal of Neurovirology, 20(3), 219-232. [More Information]
• Beinat, C., Banister, S., Hoban, J., Tsanaktsidis, J., Metaxas, A., Windhorst, A., Kassiou, M. (2014). Structure-activity relationships of N-substituted 4-(trifluoromethoxyl)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorganic & Medicinal Chemistry Letters, 24(3), 828-830. [More Information]
• Wilkinson, S., Gunosewoyo, H., Barron, M., Boucher, A., McDonnell, M., Turner, P., Morrison, D., Bennett, M., McGregor, I., Rendina, L., Kassiou, M. (2014). The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. ACS Chemical Neuroscience, 5(5), 335-339. [More Information]
• Chua, S., Kassiou, M., Ittner, L. (2014). The translocator protein as a drug target in Alzheimer's disease. Expert Review of Neurotherapeutics, 14(4), 439-448. [More Information]

2013

• Boutin, H., Prenant, C., Maroy, R., Galea, J., Greenhalgh, A., Smigova, A., Cawthorne, C., Julyan, P., Wilkinson, S., Banister, S., Kassiou, M., et al (2013). [(18)F]DPA-714: Direct comparison with [(11)C]PK11195 in a model of cerebral ischemia in rats. PloS One, 8673 (2), 1-9. [More Information]
• Beinat, C., Banister, S., McErlean, C., Kassiou, M. (2013). A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. Tetrahedron Letters, 54(39), 5345-5347. [More Information]
• Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., McGregor, I. (2013). Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the VI(A) Receptor. Neuropsychopharmacology, 38(11), 2249-2259. [More Information]
• Ribeiro, M., Vercouillie, J., Corcia, P., Arlicot, N., Erra, B., Maia, S., Bonnaud, I., Debiais, S., Kassiou, M., Guilloteau, D. (2013). Cerebral biodistribution of the PET TSPO radioligand, (18)F-DPA-714, in acute and chronic brain diseases. Journal of Labelled Compounds and Radiopharmaceuticals, 56(S1), P219-P219.
• Wilkinson, S., Price, J., Kassiou, M. (2013). Improved accessibility to the desoxy analogues of delta(9)-tetrahydrocannabinol and cannabidiol. Tetrahedron Letters, 54(1), 52-54. [More Information]
• Schollhorn-Peyronneau, M., Saba, W., Goutal, S., Damont, A., Dolle, F., Kassiou, M., Bottlaender, M., Valette, H. (2013). Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand. Drug Metabolism and Disposition, 41(1), 122-131. [More Information]
• Santiago-Ribeiro, M., Vercouillie, J., Cottier, J., Debiais, S., Bonnaud, I., Arlicot, N., Erra, B., Maia, S., Kassiou, M., Guilloteau, D. (2013). Microglia activation after acute stroke demonstrated using 18F-DPA-714 PET. Correlation with MRI. European Journal of Nuclear Medicine and Molecular Imaging, 40(S2), S208-S208. [More Information]
• Banister, S., Manoli, M., Barron, M., Werry, E., Kassiou, M. (2013). N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as sigma receptor ligands with potential neuroprotective effects. Bioorganic and Medicinal Chemistry, 21(19), 6038-6052. [More Information]
• Reekie, T., Kavanagh, M., Longworth, M., Kassiou, M. (2013). Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. Synthesis, 45(23), 3211-3227. [More Information]
• Kavanagh, M., Doddareddy, M., Kassiou, M. (2013). The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorganic & Medicinal Chemistry Letters, 23(13), 3690-3696. [More Information]
• Banister, S., Manoli, M., Kassiou, M. (2013). The development of radiotracers for imaging sigma receptors in the central nervous system (CNS) using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 56(3-4), 215-224. [More Information]
• Kahlert, J., Austin, C., Kassiou, M., Rendina, L. (2013). The fifth element in drug design: Boron in medicinal chemistry. Australian Journal of Chemistry, 66(10), 1118-1123. [More Information]
• Banister, S., Wilkinson, S., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2013). The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. [More Information]
• Austin, C., Kahlert, J., Kassiou, M., Rendina, L. (2013). The translocator protein (TSPO): A novel target for cancer chemotherapy. International Journal of Biochemistry and Cell Biology, 45(7), 1212-1216. [More Information]
• Kassiou, M., James, M., Luus, C. (2013). Translocator Protein Ligands (USA). Patent No. 8492379.

2012

• Banister, S., Rendina, L., Kassiou, M. (2012). 7-azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (sigma-2) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 22(12), 4059-4063. [More Information]
• Banister, S., Wilkinson, S., Hanani, R., Reynolds, A., Hibbs, D., Kassiou, M. (2012). A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpy-razolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. Tetrahedron Letters, 53(29), 3780-3783. [More Information]
• Banister, S., Manoli, M., Doddareddy, M., Hibbs, D., Kassiou, M. (2012). A σ1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDS). Bioorganic & Medicinal Chemistry Letters, 22(19), 6053-6058. [More Information]
• Beinat, C., Banister, S., Prehn, S., Doddareddy, M., Hibbs, D., Sako, M., Chebib, M., Tran, T., Al-Muhtasib, N., Xiao, Y., Kassiou, M. (2012). Consequences of linker length alteration of the alpha7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorganic and Medicinal Chemistry Letters, 22(7), 2380-2384. [More Information]
• Leaver, K., Reynolds, A., Bodard, S., Guilloteau, D., Chalon, S., Kassiou, M. (2012). Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. ACS Chemical Neuroscience, 3(2), 114-119. [More Information]
• Scarf, A., Luus, C., Da Pozzo, E., Selleri, S., Guarino, C., Martini, C., Ittner, L., Kassiou, M. (2012). Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa). Current Molecular Medicine, 12(4), 488-493. [More Information]
• Moussa, I., Banister, S., Manoli, M., Doddareddy, M., Cui, J., Mach, R., Kassiou, M. (2012). Exploration of ring size in a series of cyclic vicinal diamines with sigma(1) receptor-affinity. Bioorganic & Medicinal Chemistry Letters, 22(17), 5493-5497. [More Information]
• Gilmore, A., Heblinski, M., Reynolds, A., Kassiou, M., Connor, M. (2012). Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. British Journal of Pharmacology, 167(5), 1076-1088. [More Information]
• Arlicot, N., Vercouillie, J., Ribeiro, M., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Corcia, P., Stabin, M., Reynolds, A., Kassiou, M., et al (2012). Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 39(4), 570-578. [More Information]
• Scarf, A., Aumann, K., Kassiou, M. (2012). Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18 kDa)? Current Molecular Medicine, 12(4), 387-397. [More Information]
• Banister, S., Wilkinson, S., Connor, M., McGregor, I., Kassiou, M. (2012). Medicinal chemists breaking bad: The clandestine rational design of cannabimimetic indoles as drugs of abuse. The clandestine rational design of cannabimimetic indoles as drugs of abuse. Frontiers in medicinal chemistry, Australia: RACI.
• Corcia, P., Tauber, C., Vercoullie, J., Arlicot, N., Prunier, C., Praline, J., Nicolas, G., Venel, Y., Hommet, C., Baulieu, J., Kassiou, M., et al (2012). Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PloS One, 7(12), 1-7. [More Information]
• Endres, C., Coughlin, J., Gage, K., Watkins, C., Kassiou, M., Pomper, M. (2012). Radiation dosimetry and biodistribution of the TSPO ligand (11)C-DPA-713 in humans. The Journal of Nuclear Medicine, 53(2), 330-335. [More Information]
• Gosling, J., Baker, S., Haynes, J., Kassiou, M., Pouton, C., Warfe, L., White, P., Scammells, P. (2012). Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic N6-Substituents as Adenosine A1 Receptor Agonists. ChemMedChem: chemistry enabling drug discovery, 7(7), 1191-1201. [More Information]
• Fulham, M., Kassiou, M., Greguric, I., Thomson, S., Eberl, S., Tiam, P., Mattner, F., Henderson, D., Fulton, R., Katsifis, A., et al (2012). Synthesis and in vivo evaluation of arylalkyl 4-benzyl piperidines as radioligands for sigma receptors. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
• Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C., Kassiou, M., Hunt, G., McGregor, I. (2012). The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor-Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 24(7), 1012-1029. [More Information]
• Banister, S., Kassiou, M. (2012). The Therapeutic Potential of Sigma (sigma) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. Current Pharmaceutical Design, 18(7), 884-901. [More Information]

2011

• Dolle, F., Kuhnast, B., Damont, A., van Camp, N., Kassiou, M., Tavitian, B., Boisgard, R. (2011). [18F]DPA-716 as a candidate for imaging the TSPO 18 kDa with PET: Radiosynthesis and comparative evaluation ([11C]DPA-713/[18F]DPA-714) in a rat model of neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S275-S275.
• Vercouillie, J., Ribeiro, M., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Reynolds, A., Kassiou, M., Guilloteau, D., Corcia, P. (2011). Biodistribution of the TSPO radioligand (18)F-DPA-714 in healthy volunteers. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S255-S255.
• Issa, F., Kassiou, M., Rendina, L. (2011). Boron in drug discovery: Carboranes as unique pharmacophores in biologically active compounds. Chemical Reviews, 111(9), 5701-5722. [More Information]
• Drake, C., Boutin, H., Jones, M., Denes, A., McColl, B., Selvarajah, J., Hulme, S., Georgiou, R., Hinz, R., Gerhard, A., Kassiou, M., et al (2011). Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 25(6), 1113-1122. [More Information]
• Dolle, F., Le Helleix, S., Schollhorn-Peyronneau, M., Saba, W., Banister, S., Tournier, N., Valette, H., Kassiou, M. (2011). Carbon-11-labelling of a novel, trishomocubane-derived, high affinity and selectivity DAT ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S276-S276.
• Moussa, I., Banister, S., Akladios, F., Chua, S., Kassiou, M. (2011). Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine sigma(1) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 21(19), 5707-5710. [More Information]
• Banister, S., Moussa, I., Jorgensen, W., Chua, S., Kassiou, M. (2011). Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 21(12), 3622-3626. [More Information]
• Banister, S., Yoo, D., Chua, S., Cui, J., Mach, R., Kassiou, M. (2011). N-arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (sigma) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 21(18), 5289-5292. [More Information]
• Ribeiro, M., Vercouillie, J., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Reynolds, A., Kassiou, M., Guilloteau, D., Corcia, P. (2011). P-167 The potential interest of the PET radioligand (18)F-DPA-714 in neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S256-S256.
• Martin, A., Boisgard, R., Kassiou, M., Dolle, F., Tavitian, B. (2011). Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [(18)F]DPA-714. Molecular Imaging and Biology, 13(1), 10-15. [More Information]
• Boucher, A., Arnold, J., Hunt, G., Spiro, A., Spencer, J., Brown, C., McGregor, I., Bennett, M., Kassiou, M. (2011). Resilience and Reduced C-FOS Expression in P2X7 Receptor Knockout Mice Exposed to Repeated Forced Swim Test. Neuroscience, 189, 170-177. [More Information]
• Crossley, E., Issa, F., Scarf, A., Kassiou, M., Rendina, L. (2011). Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells. Chemical Communications, 47(44), 12179-12181. [More Information]
• Moussa, I., Banister, S., Giboureau, N., Meikle, S., Kassiou, M. (2011). Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agent. Bioorganic and Medicinal Chemistry Letters, 21(22), 6820-6823. [More Information]
• Damont, A., Boisgard, R., Kuhnast, B., Lemee, F., Raggiri, G., Scarf, A., Da Pozzo, E., Selleri, S., Martini, C., Tavitian, B., Kassiou, M., et al (2011). Synthesis of 6-[(18)F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. Bioorganic and Medicinal Chemistry Letters, 21(16), 4819-4822. [More Information]
• Scarf, A., Kassiou, M. (2011). The translocator protein. The Journal of Nuclear Medicine, 52(5), 677-680. [More Information]
• Banister, S., Moussa, I., Beinat, C., Reynolds, A., Schiavini, P., Jorgensen, W., Kassiou, M. (2011). Trishomocubane as a Scaffold for the Development of Selective Dopamine Transporter (DAT) Ligands. Bioorganic and Medicinal Chemistry Letters, 21(1), 38-41. [More Information]

2010

• Banister, S., Clegg, J., Hanani, R., Kassiou, M. (2010). 11-{[2-(3-fluorophenyl)ethyl](methyl)-amino}pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]-undecan-8-one. Acta Crystallographica. Section E: Structure Reports Online, 66(10), o2693-o2693. [More Information]
• Kassiou, M., James, M. (2010). 2-Arylpyrazolo[L,5-a]Pyrimidin-3-yl Acetamide Deriv As Ligands For Translocator Protein. Patent No. 2008/10473. South Africa.
• Naidoo (Naidoo-Variawa), S., Lehnert, W., Kassiou, M., Banati, R., Meikle, S. (2010). Attenuation correction for the large non-human primate brain imaging using microPET. Physics in Medicine and Biology, 55(8), 2351-2363. [More Information]
• Morrison, D., Issa, F., Bhadbhade, M., Groebler, L., Witting, P., Kassiou, M., Rutledge, P., Rendina, L. (2010). Boronated phosphonium salts containing arylboronic acid, closo-carborane, or nido-carborane: synthesis, X-ray diffraction, in vitro cytotoxicity, and cellular uptake. Journal of Biological Inorganic Chemistry, 15(8), 1305-1318. [More Information]
• Moussa, I., Banister, S., Beinat, C., Giboureau, N., Reynolds, A., Kassiou, M. (2010). Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. Journal of Medicinal Chemistry, 53(16), 6228-6239. [More Information]
• Giboureau, N., Aumann, K., Beinat, C., Kassiou, M. (2010). Development of vesicular acetylcholine transporter ligands: Molecular probes for Alzheimer's disease. Current Bioactive Compounds, 6(3), 129-155. [More Information]
• Abraham, M., Boisgard, R., Theze, B., Van Camp, N., Kuhnast, B., Damont, A., Kassiou, M., Dolle, F., Tavitian, B. (2010). Evaluation of the PBR/TSPO radioloigand [18F]DPA-714 in a rat model of focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 30(1), 230-241. [More Information]
• Banister, S., Roeda, D., Dolle, F., Kassiou, M. (2010). Fluorine-18 chemistry for PET: A concise introduction. Current Radiopharmaceuticals, 3(2), 68-80. [More Information]
• Beinat, C., Banister, S., Moussa, I., Reynolds, A., McErlean, C., Kassiou, M. (2010). Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists. Current Medicinal Chemistry, 17(34), 4166-4190. [More Information]
• Fulton, R., Meikle, S., Kyme, A., Zhou, W., Popovic, K., Kassiou, M., Akhtar, M. (2010). Motion-corrected microPET brain imaging of conscious rats. 2009 World Molecular Imaging Conference, USB drive/online: Online.
• Banister, S., Moussa, I., Jordan, M., Coster, M., Kassiou, M. (2010). Oxo-bridged isomers of aza-trishomocubane sigma (o) receptor ligands: Synthesis, in vitro binding, and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 20(1), 145-148. [More Information]
• Gunosewoyo, H., Kassiou, M. (2010). P2X purinergic receptor ligands: Recently patented compounds. Expert Opinion on Therapeutic Patents, 20(5), 625-646. [More Information]
• Giboureau, N., Mat Som, I., Boucher, A., Guilloteau, D., Kassiou, M. (2010). PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT). Current Topics in Medicinal Chemistry, 10(15), 1569-1583. [More Information]
• Reynolds, A., Hanani, R., Hibbs, D., Damont, A., Da Pozzo, E., Selleri, S., Dolle, F., Martini, C., Kassiou, M. (2010). Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO). Bioorganic and Medicinal Chemistry Letters, 20(19), 5799-5802. [More Information]
• Luus, C., Hanani, R., Reynolds, A., Kassiou, M. (2010). The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? Journal of Labelled Compounds and Radiopharmaceuticals, 53(7), 501-510. [More Information]

2009

• Valette, H., Xiao, Y., Schollhorn-Peyronneau, M., Damont, A., Kosikowski, A., Wei, Z., Kassiou, M., Kellar, K., Dolle, F., Bottlaender, M. (2009). 18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors-In Vitro Binding Properties and PET Studies in Baboons. The Journal of Nuclear Medicine, 50(8), 1349-1355. [More Information]
• Doorduin, J., Klein, H., Dierckx, R., James, M., Kassiou, M., De Vries, E. (2009). [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: A comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Molecular Imaging and Biology, 11(6), 386-398. [More Information]
• Damont, A., van Camp, N., Kuhnast, B., Hinnen, F., Boisgard, R., Chauveau, F., Boutin, H., Probst, K., Clark, J., Katsifis, A., Kassiou, M. (2009). [18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106 as potent PBR pet-imaging candidates: Radiosynthesis and comparative studies. Journal of Labelled Compounds and Radiopharmaceuticals, 52(S1), S122-S122.
• Banister, S., Coster, M., Kassiou, M. (2009). A versatile polycyclic scaffold for the discovery of selective sigma (sigma) receptor ligands. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
• Truong, L., Allbutt, H., Coster, M., Kassiou, M., Henderson, J. (2009). Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+ parafascicular lesions. Brain Research Bulletin, 78(2-3), 91-96. [More Information]
• Kassiou, M., Banati, R., Holsinger, D., Meikle, S. (2009). Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 78(2-3), 105-108. [More Information]
• Chauveau, F., Van Camp, N., Dolle, F., Kuhnast, B., Hinnen, F., Damont, A., Boutin, H., James, M., Kassiou, M., Tavitian, B. (2009). Comparative evaluation of the translocator protein radioligands (11)C-DPA-713, (18)F-DPA-714, and (11)C-PK11195 in a rat model of acute neuroinflammation. The Journal of Nuclear Medicine, 50(3), 468-476. [More Information]
• Kassiou, M. (2009). Discovery of new therapeutic immunomodulator drugs as a pathway for treating brain disease. Plant Nutraceuticals and Bioactive Molecules: A Growth Opportunity for the Pharmaceutical Industry in Australia and India, N/A: N/A.
• Warraich, S., Allbutt, H., Billing, R., Radford, J., Coster, M., Kassiou, M., Henderson, J. (2009). Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Research Bulletin, 78(2-3), 85-90. [More Information]
• Edington, A., McKinzie, A., Reynolds, A., Kassiou, M., Ryan, R., Vandenberg, R. (2009). Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport. Journal of Biological Chemistry, 284(52), 36424-36430. [More Information]
• Kassiou, M. (2009). Imaging immune response in the CNS - Applications for therapeutic development. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
• Endres, C., Pomper, M., James, M., Uzuner, O., Hammoud, D., Watkins, C., Reynolds, A., Hilton, J., Dannals, R., Kassiou, M. (2009). Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. The Journal of Nuclear Medicine, 50(8), 1276-1282. [More Information]
• Leaver, K., Allbutt, H., Creber, N., Kassiou, M., Henderson, J. (2009). Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. Brain Research Bulletin, 80(6), 397-402. [More Information]
• Kassiou, M., James, M., Luus, C. (2009). Patent No. WO2009079683 (A1).
• Gunosewoyo, H., Coster, M., Bennett, M., Kassiou, M. (2009). Purinergic P2X(7) receptor antagonists:Chemistry and fundamentals of biological screening. Bioorganic and Medicinal Chemistry, 17(14), 4861-4865. [More Information]
• Dolle, F., Luus, C., Reynolds, A., Kassiou, M. (2009). Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Current Medicinal Chemistry, 16(22), 2899-2923. [More Information]
• Reynolds, A., Kassiou, M. (2009). Recent advances in the Mitsunobu reaction: Modifications and applications to biologically active molecules. Current Organic Chemistry, 13(16), 1610-1632. [More Information]
• Moussa, I., Coster, M., Kassiou, M. (2009). Synthesis and pharmacological evaluation of novel sigma receptor ligands. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
• Scarf, A., Ittner, L., Kassiou, M. (2009). The translocator protein (18 kDa): Central nervous system disease and drug design. Journal of Medicinal Chemistry, 52(3), 581-592. [More Information]
• Ioppolo, J., Kassiou, M., Rendina, L. (2009). Water-soluble phosphonium salts containing 1,12-dicarba-closo-dodecaborane(12). Tetrahedron Letters, 50(47), 6457-6461. [More Information]
• Dolle, F., Damont, A., Valette, H., Hinnen, F., Kuhnast, B., Saba, W., Schollhorn-Peyronneau, M., Kozikowski, A., Bottlaender, M., Kassiou, M. (2009). ZW-102 and ZW-104, two novel fluorine-18 labelled radioligands for imaging nicotinic acetylcholine receptors with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 52(S1), S364.

2008

• van Dijk, A., Johnston, C., Allbutt, H., Kassiou, M., Henderson, J. (2008). Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions. Behavioural Brain Research, 190(1), 14-21. [More Information]
• Gunosewoyo, H., Liu, G., Bennett, M., Coster, M., Kassiou, M. (2008). Cubyl amides: Novel P2X(7) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 18(13), 3720-3723. [More Information]
• Besret, L., Dolle, F., Herard, A., Guillermier, M., Demphel, S., Hinnen, F., Coulon, C., Ottaviani, M., Bottlaender, M., Hantraye, P., Kassiou, M. (2008). Dopamine D1 Receptor Imaging in the Rodent and Primate Brain Using the Isoquinoline (+)-[(11)C]A-69024 and Positron Emission Tomography. Journal of Pharmaceutical Sciences, 97(7), 2811-2819. [More Information]
• James, M., Fulton, R., Vercoullie, J., Henderson, D., Garreau, L., Chalon, S., Dolle, F., Selleri, S., Guilloteau, D., Kassiou, M. (2008). DPA-714, a New Translocator Protein-Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. The Journal of Nuclear Medicine, 49(5), 814-822. [More Information]
• Leaver, K., Allbutt, H., Creber, N., Kassiou, M., Henderson, J. (2008). Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clinical and Experimental Pharmacology and Physiology, 35(11), 1388-1394. [More Information]
• Henderson, J., Lanciego, J., Smith, Y., Gundlach, A., Kassiou, M. (2008). Proceedings of the 2007 International Brain Research Organisation Satellite Meeting "Movement Disorders: Focus on the Thalamus and Basal Ganglia" held in Sydney, Australia, 10-11 July, 2007. Brain Research Bulletin, 78(2-3), 53-54. [More Information]
• Fulton, R., Kyme, A., Zhou, V., Leaver, K., Kassiou, M., Lehnert, W., Meikle, S. (2008). Progress towards microPET imaging of small, awake laboratory animals. 2008 World Molecular Imaging Congress, Europe: World Molecular Imaging Congress.
• Guenther, K., Hambley, T., Kassiou, M. (2008). Radiolabelled probes for imaging multidrug resistance using single photon emission tomography (SPECT) and positron emission tomography (PET). In Nicola Antonio Colabufo (Eds.), Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment, (pp. 291-320). India: Research Signpost.
• Damont, A., Hinnen, F., Kuhnast, B., Schollhorn-Peyronneau, M., James, M., Luus, C., Tavitian, B., Kassiou, M., Dolle, F. (2008). Radiosynthesis of [(18)F]DPA-714, a selective radioligand for imaging the translocator protein (18 kDa) PET. Journal of Labelled Compounds and Radiopharmaceuticals, 51(7-8), 286-292. [More Information]
• Dolle, F., Langle, S., Roger, G., Fulton, R., Lagnel, B., Henderson, D., Hinnen, F., Paine, T., Coster, M., Valette, H., Kassiou, M., et al (2008). Synthesis and In-Vivo Evaluation of [(11)C]p-PVP-MEMA as a PET Radioligand for Imaging Nicotinic Receptors. Australian Journal of Chemistry, 61(6), 438-445. [More Information]

2007

• Doorduin, J., Klein, H., James, M., Kassiou, M., Dierckx, R., Vries, E. (2007). (18F)DPA-714 as a novel PET tracer for PBR: A comparison with (11C)PK11195 in a rat model of HSV encephalitis. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Banister, S., Clegg, J., Coster, M., Jolliffe, K., Kassiou, M. (2007). (1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.02,7]-undeca-4,9-diene-3,6-diol. Acta Crystallographica. Section E: Structure Reports Online, E63(0), o92-o93. [More Information]
• Emond, P., Mavel, S., Zea-Ponce, Y., Kassiou, M., Garreau, L., Bodard, S., Drossard, M., Chalon, S., Guilloteau, D. (2007). (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 34(8), 967-971. [More Information]
• Boutin, H., Chauveau, F., Thominiaux, C., Gregoire, M., James, M., Trebossen, R., Hantraye, P., Dolle, F., Tavitian, B., Kassiou, M. (2007). 11C-DPA-713: A novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. The Journal of Nuclear Medicine, 48(4), 573-581. [More Information]
• Kozikowski, A., Chellappan, S., Henderson, D., Fulton, R., Giboureau, N., Xiao, Y., Wei, Z., Guilloteau, D., Emond, P., Dolle, F., Kassiou, M., et al (2007). Acetylenic pyridines for use in PET imaging of nicotinic receptors. ChemMedChem: chemistry enabling drug discovery, 2(0), 54-57. [More Information]
• Quinlivan, M., Chalon, S., Vergote, J., Henderson, J., Katsifis, A., Kassiou, M., Guilloteau, D. (2007). Decreased vesicular acetylcholine transporter and alpha-4beta-2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neuroscience Letters, 415(0), 97-101. [More Information]
• James, M., Fulton, R., Vercouille, J., Henderson, D., Garreau, L., Eberl, S., Chalon, S., Selleri, S., Dolle, F., Guilloteau, D., Kassiou, M. (2007). DPA-714 A new translocator protein (18kDa) ligand: Synthesis, radiofluorination and pharmacological characterisation. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Mavel, S., Zea-Ponce, Y., Garreau, L., Chalon, S., Kassiou, M., Guilloteau, D., Emond, P. (2007). E-((R,R) and (S,S))-5-(125I)-AOIBV: Potential SPECT tracers in vivo studies of the vesicular AcetylCholine Transporter (VACht). 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Giboureau, N., Emond, P., Fulton, R., Henderson, D., Chalon, S., Garreau, L., Roselt, P., Eberl, S., Mavel, S., Bodard, S., Fulham, M., Kassiou, M., et al (2007). Ex vivo and in vivo evaluation of (2R,3R)-5-[18F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse (New York), 61(12), 962-670. [More Information]
• Naidoo (Naidoo-Variawa), S., Lehnert, W., Hey-Cunningham, A., Kench, P., Kassiou, M., Banati, R., Meikle, S. (2007). High-resolution imaging of the large non-human primate brain using microPET: a feasibility study. Physics in Medicine and Biology, 52(22), 6627-6638. [More Information]
• Collier, T., Waterhouse, R., Kassiou, M. (2007). Imaging sigma receptors: Applications in drug development. Current Pharmaceutical Design, 13(0), 51-72. [More Information]
• Kassiou, M. (2007). Molecular imaging in drug development (EDITORIAL). Current Pharmaceutical Design, 13(1), 1-1. [More Information]
• Gunosewoyo, H., Coster, M., Kassiou, M. (2007). Molecular probes for P2X7 receptor studies. Current Medicinal Chemistry, 14(14), 1505-1523. [More Information]
• Cagnin, A., Kassiou, M., Meikle, S., Banati, R. (2007). Positron emission tomography imaging of neuroinflammation. Neurotherapeutics, 4(3), 443-452. [More Information]
• Kassiou, M., Chellappan, S., Henderson, D., Fulton, R., Giboureau, N., Xiao, Y., Wei, Z., Guilloteau, D., Emond, P., Dolle, F., et al (2007). Radiosynthesis and preliminary evaluation of ZW-90 and ZW-110, two novel acetylenic pyridines for imaging nicotonic receptors. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Giboureau, N., Chalon, S., Garreau, L., Kassiou, M., Emond, P., Guilloteau, D. (2007). Rat distribution of (18F)-Fuoropropoxy- and (18F)-Fluoroethoxybenzovesamicol, as PET radioligands for the vesicular acetylcholine transporter (VACht). 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Creelman, A., Thominiaux, C., Chauveau, F., Fulton, R., Kuhnast, B., Henderson, D., Boutin, H., Selleri, S., McGregor, I., Hantraye, P., Kassiou, M., et al (2007). Synthesis and evaluation of the translocator protein (18kDa) (TSPO) ligand (11C)DPA0715 in rat and non-human primate. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Langley, S., Roger, G., Fulton, R., Lagnel, B., Henderson, D., Hinnen, F., Bottlaender, M., Dolle, F., Kassiou, M. (2007). Synthesis and in vivo evaluation of (11c)P-PVP-MEMA as a PET radioligand for Imaging nicotonic receptors. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Liu, X., Banister, S., Christie, M., Banati, R., Meikle, S., Coster, M., Kassiou, M. (2007). Trishomocubanes: Novel sigma ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 555(1), 37-42. [More Information]

2006

• Truong, L., Allbutt, H., Kassiou, M., Henderson, J. (2006). Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behavioural Brain Research, 169(1), 1-9. [More Information]
• James, M., Selleri, S., Kassiou, M. (2006). Development of ligands for the peripheral benzodiazepine receptor. Current Medicinal Chemistry, 13(17), 1991-2001. [More Information]
• Thominiaux, C., Dolle, F., James, M., Bramoulle, Y., Boutin, H., Besret, L., Gregoire, M., Valette, H., Bottlaender, M., Tavitian, B., Kassiou, M., et al (2006). Improved synthesis of the peripheral benzodiazepine receptor ligand C-11 DPA-713 using C-11 methyl triflate. Applied Radiation and Isotopes, 64(5), 570-573. [More Information]
• Cagnin, A., Kassiou, M., Meikle, S., Banati, R. (2006). In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurologica Scandinavica, 114(Supplement 185), 107-114. [More Information]
• Thominiaux, C., de Bruin, B., Bramoulle, Y., Hinnen, F., Demphel, S., Valette, H., Bottlaender, M., Besret, L., Kassiou, M., Dolle, F. (2006). Radiosynthesis of (E)-N-(2- C-11 methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist. Applied Radiation and Isotopes, 64(3), 348-354. [More Information]
• Assaad, T., Mavel, S., Parsons, S., Kruse, S., Galineau, L., Allouchi, H., Kassiou, M., Chalon, S., Guilloteau, D., Emond, P. (2006). Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. Bioorganic and Medicinal Chemistry Letters, 16(10), 2654-2657. [More Information]
• Vercouillie, J., Mavel, S., Galineau, L., Ragusa, T., Innis, R., Chalon, S., Kassiou, M., Dolle, F., Besnard, J., Guilloteau, D., et al (2006). Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorganic and Medicinal Chemistry Letters, 16(5), 1297-1300. [More Information]
• Issa, F., Kassiou, M., Chan, H., McLeod, M. (2006). Synthesis and radiolabelling of ipratropium and tiotropium for use as PET ligands in the study of inhaled drug deposition. Australian Journal of Chemistry, 59(1), 53-58. [More Information]

2005

• Kassiou, M. (2005). Capabilities of PET and SPECT in pre-clinical and clinical research. Current Pharmaceutical Design, 11(25), 3201-3201. [More Information]
• Liu, X., Mattner, F., Katsifis, A., Christie, M., Kassiou, M. (2005). Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain. Medicinal Chemistry, 1(1), 31-38. [More Information]
• Kassiou, M., Meikle, S., Banati, R. (2005). Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Research Reviews, 48(2), 207-210. [More Information]
• Kassiou, M., Bruin, B., Demphel, S., Besret, L., Hinnen, F., Dolle, F., Bramoulle, Y., Thominiaux, C., Bottlaender, M. (2005). Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor ligand. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
• Nikpour (Mohamed), A., Eberl, S., Fulham, M., Kassiou, M., Zaman, A., Henderson, D., Beveridge, S., Constable, C., Lo, S. (2005). Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and F-18-FDG PET imaging). European Journal of Nuclear Medicine and Molecular Imaging, 32(2), 180-185. [More Information]
• Meikle, S., Kench, P., Kassiou, M., Banati, R. (2005). Small animal SPECT and its place in the matrix of molecular imaging technologies. Physics in Medicine and Biology, 50(22), R45-R61. [More Information]
• Zea-Ponce, Y., Mavel, S., Assaad, T., Kruse, S., Parsons, S., Emond, P., Chalon, S., Giboureau, N., Kassiou, M., Guilloteau, D. (2005). Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorganic and Medicinal Chemistry, 13(3), 745-753. [More Information]
• Kassiou, M., Dannals, R., Liu, X., Wong, D., Ravert, H., Scheffel, U. (2005). Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorganic and Medicinal Chemistry, 13(11), 3623-3626. [More Information]
• Fulham, M., Kassiou, M., Dolle, F., Thomson, S., Henderson, D., James, M., Eberl, S., Fulton, R., Allan, R. (2005). Synthesis and In Vivo Evaluation of a Novel Peripheral Benzodiazepine Receptor PET Radioligand. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
• James, M., Fulton, R., Henderson, D., Eberl, S., Meikle, S., Thomson, S., Allan, R., Dolle, F., Fulham, M., Kassiou, M. (2005). Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorganic and Medicinal Chemistry, 13(22), 6188-6194. [More Information]

2004

• Henderson, D., Eberl, S., Thomson, S., Smith, A., Allan, R., Fulham, M., Loiacono, R., Kassiou, M. (2004). 3-Pyridyl Ethers As Spect Radioligands For Imaging Nicotinic Acetylcholine Receptors. Applied Radiation and Isotopes, 60(5), 669-676. [More Information]
• Katsifis, A., Kassiou, M. (2004). Development Of Radioligands For In Vivo Imaging Of Gaba(A)-Benzodiazepine Receptors. Mini - Reviews in Medicinal Chemistry, 4(8), 909-921. [More Information]
• Dolle, F., Valette, H., Demphel, S., Coulon, C., Ottaviani, M., Bottlaender, M., Kassiou, M. (2004). Radiosynthesis And In Vivo Evaluation Of [11C]Ro-547312: A Novel Nr1/2B Subtype Selective Nmda Receptor Radioligand. Journal of Labelled Compounds and Radiopharmaceuticals, 47(13), 911-920. [More Information]
• Roger, G., Dolle, F., de Bruin, B., Liu, X., Besret, L., Bramoulle, Y., Coulon, C., Ottaviani, M., Bottlaender, M., Valette, H., Kassiou, M. (2004). Radiosynthesis And Pharmacological Evaluation Of [11C]Emd-95885: A High Affinity Ligand For Nr2B-Containing Nmda Receptors. Bioorganic and Medicinal Chemistry, 12(12), 3229-3237. [More Information]
• Roselt, P., Meikle, S., Kassiou, M. (2004). The Role Of Positron Emission Tomography In The Discovery And Development Of New Drugs; As Studied In Laboratory Animals. European Journal of Drug Metabolism and Pharmacokinetics, 29(1), 1-6. [More Information]

2003

• Kassiou, M., Katsifis, A. (2003). PET radiochemistry in drug development and evaluation. Chemistry in Australia, 70(5), 10-12.
• Katsifis, A., Mardon, K., Mattner, F., Loc'h, C., McPhee, M., Dikic, B., Kassiou, M., Ridley, D. (2003). Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. Nuclear Medicine and Biology, 30(2), 191-198. [More Information]
• Feng, D., Kassiou, M., Fulham, M., Wong, K., Elberl, S. (2003). Quantification of 5-[123I]iodo-A-85380 in nonhuman primates using spect: parameter identifiability and stabilitty. Modelling and Control in Biomedical Systems 2003 (Including Biological Systems), UK: Pergamon.
• Quinlivan, M., Mattner, F., Papazian, V., Zhou, J., Katsifis, A., Emond, P., Chalon, S., Kozikowski, A., Guilloteau, D., Kassiou, M. (2003). Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter. Nuclear Medicine and Biology, 30(7), 741-746. [More Information]
• Roger, G., Lagnel, B., Besret, L., Bramoulle, Y., Coulon, C., Ottaviani, M., Kassiou, M., Bottlaender, M., Valette, H., Dolle, F. (2003). Synthesis, radiosynthesis and In Vivo evaluation of 5-[3-(4-Benzylpiperidin-1-yl) prop-1-ynyl]-1, 3-dihydrobenzoimidazol-2-[11C] one, as a potent NR 1A/2B subtype selective NMDA PET radiotracer. Bioorganic and Medicinal Chemistry, 11, 5401-5408. [More Information]

2002

• Kassiou, M., Loc'h, C., Bottlaender, M., Mardon, K., Ottaviani, M., Coulon, C., Katsifis, A., Maziere, B. (2002). (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nuclear Medicine and Biology, 29(3), 295-302. [More Information]
• Kassiou, M., Bottlaender, M., Loc'h, C., Dolle, F., Musachio, J., Coulon, C., Ottaviani, M., Dannals, R., Maziere, B. (2002). Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors. Synapse (New York), 45(2), 95-104. [More Information]
• Kassiou, M., Loc'h, C., Dolle, F., Musachio, J., Dolci, L., Crouzel, C., Dannals, R., Maziere, B. (2002). Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies. Applied Radiation and Isotopes, 57(5), 713-717. [More Information]

2001

• Kassiou, M., Eberl, S., Meikle, S., Birrell, A., Constable, C., Fulham, M., Wong, D., Musachio, J. (2001). In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nuclear Medicine and Biology, 28, 165-175.
• Kassiou, M., Mardon, K., Mattner,, F., Katsifis, A., Dikic, B. (2001). Pharmacological evaluation of (+)-2-[123I]A-69024: A radioligand for in vivo studies of dopamine D1 receptors. Life Sciences, 69, 669-675.
• Liu, X., Christie, M., Kassiou, M., Nuwayhid, S., Werling, L. (2001). Trishomocubanes: Novel sigma-ligands modulate amphetamine-stimulated [3H]dopamine release. European Journal of Pharmacology, 422, 39-45. [More Information]
• Liu, X., Kassiou, M., Christie, M., Hambley, T. (2001). Trishomocubanes: requirements for sigma receptor binding and subtype selectivity. Australian Journal of Chemistry, 54, 31-36.